Last reviewed · How we verify
CT-011
At a glance
| Generic name | CT-011 |
|---|---|
| Also known as | Anti-PD1 Antibody, Pidilizumab, Monoclonal Antibody CT-011 |
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation (PHASE2)
- Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission (PHASE2)
- CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection (PHASE1)
- Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma (PHASE1)
- Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer (PHASE2)
- Gemcitabine and CT-011 for Resected Pancreatic Cancer (PHASE2)
- Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission (PHASE2)
- CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT-011 CI brief — competitive landscape report
- CT-011 updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI